SAN FRANCISCO – Jaguar Health, Inc. (NASDAQ: JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences,...
MindBio Therapeutics Corp. announced it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder....
The Psychedelic Education Market is Expanding Rapidly This rapid expansion is occurring in response to growth— both real and perceived- in the greater...
Discover the transformative synergy of forest bathing and psychedelics for a deeper connection with nature and improved well-being.
Booty bumping may sound like a fun way to party, but boofing ketamine comes with some hefty risks.
Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments...
Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments...
–Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”)...
Cybin Inc. (NYSE: CYBN) announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for CYB004,...
Explore how psychedelic-assisted therapy, particularly with psilocybin, offers new, promising avenues for treating nicotine and other addictions.